Worth reading
39Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
30.7
% (year-on-year change in revenue)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Annual updateInvestment amount by sectorField Investment in Mykarte and investment in platform development / Amount ¥98 million / Period Second quarter of the fiscal year ending December 2026
Key initiatives
01Expand the platform business for PHR services and data use by disease area
02Promote data portability through diverse data linkages, including the linkage of test results through the MeDaCa service
03Strengthen personalized services for users, including the PHR data business and treatment support through disease simulation
04Strengthen the development of the medical institution network by providing services to local governments, including deemed health checkups and prevention of disease progression
05Accelerate adoption of Mykarte ONC in collaboration with academic societies and other organizations
06Launch a medical education platform business for patients
07Strengthen data solutions through ePRO and registry studies for clinical research
08Expand the business footprint through clinical research projects for pharmaceutical companies
09Advance platform enhancements to drive a step change in the data business
10Promote the use of PHR in targeted disease areas
11Expand the business by providing PHR platforms organized by disease area
12Increase revenue by developing a platform in the oncology area
13Develop the data and research business
14Launch and promote the medical education platform business for patients
15Expand medical institution use in targeted disease areas and regions
16Expand the business of preventing disease progression and encouraging medical consultations for insurers
17Launch and promote a merchandise business combined with the use of PHR data
18Expand the data and research business
19Strengthen data solutions through ePRO and other services for clinical research
20Expand the medical education platform business for patients
21Launch treatment support through disease simulation
22Expand the merchandise business combined with the use of PHR data
Segment targetSegment Primary care / Indicator Number of medical institutions contracted for Mykarte / Target value 10,000 institutions / Timing 2027, Segment Oncology / Indicator Number of medical institutions adopting the service / Target value 150 institutions (32%) / Timing 2027
Non-financial targetsIndicator name Number of medical institutions contracted for Mykarte / Target value 10,000 institutions / Timing 2027, Indicator name Number of medical institutions adopting Mykarte ONC / Target value 100 institutions / Timing 2026, Indicator name Number of medical institutions adopting Mykarte ONC / Target value 150 institutions (32%) / Timing 2027
Size of the Target MarketMarket B2B / Dimensions Approximately ¥250–¥360 billion / Breakdown Disease solutions business: ¥167.7 billion; Mykarte business: ¥78.5–¥193.5 billion / Source Fuji Keizai, “Future Prospects for the Seamless Integration and Cloudification of Healthcare IT and the Healthcare Big Data Business, No. 2” (2020); Yano Research Institute, “The Current State and Outlook of the Insurtech Market in Life Insurance Companies 2022”; Dentsu, “Advertising Expenditures in Japan”; Fuji Chimera Research Institute, “Comprehensive Survey of Wearable and Healthcare Businesses 2023”, Market B2M（B2B2M） / Dimensions Approximately ¥80–¥180 billion / Breakdown Mykarte business: ¥48.6–¥145.7 billion; real-world data business: ¥32.0 billion / Source Fuji Keizai, “Future Prospects for the Seamless Integration and Cloudification of Healthcare IT and the Healthcare Big Data Business, No. 1” (2020); Cabinet Office Secretariat of Science, Technology and Innovation Policy, “Strategic Innovation Creation Program (SIP): Strategy and Research and Development Plan for Building and Socially Implementing an Integrated Healthcare System”, Market B2B2C / Dimensions Approximately ¥660 billion (¥661.0 billion) / Breakdown Mykarte business and services for insurers / Source Ministry of Economy, Trade and Industry, “Promoting Health and Productivity Management” (March 2024), Market Target market (internal medicine institutions) / Dimensions 64,000 institutions / Breakdown Cardiology: 13,000; diabetology: 4,000; other internal medicine: 47,000 / Source Not disclosed, Market Target patients / Dimensions Hypertension: 24.5 million; diabetes: 8 million / Breakdown Not disclosed / Source Not disclosed
Risks identified by the company
Handling of personal information: Patient privacy may be compromised by unforeseen events, such as the leakage of personal information
Competition: Competitive advantages may decline due to the entry of companies with high name recognition and broad customer bases, among other factors
Various regulations: The company may be required to respond to revisions, abolition or introduction of relevant laws and regulations or industry association rules
Seasonality of revenue: Revenue and profit tend to be concentrated in the fourth quarter, when the fiscal-year results of foreign-affiliated pharmaceutical companies are concentrated
| Item | Details |
|---|---|
| Plan name | Current medium-term management plan |
| Plan period | FY26〜FY28 |
| Progress against the plan | Annual update |
| Investment amount by sector | Field Investment in Mykarte and investment in platform development / Amount ¥98 million / Period Second quarter of the fiscal year ending December 2026 |
| Segment target | Segment Primary care / Indicator Number of medical institutions contracted for Mykarte / Target value 10,000 institutions / Timing 2027, Segment Oncology / Indicator Number of medical institutions adopting the service / Target value 150 institutions (32%) / Timing 2027 |
| Non-financial targets | Indicator name Number of medical institutions contracted for Mykarte / Target value 10,000 institutions / Timing 2027, Indicator name Number of medical institutions adopting Mykarte ONC / Target value 100 institutions / Timing 2026, Indicator name Number of medical institutions adopting Mykarte ONC / Target value 150 institutions (32%) / Timing 2027 |
| Key initiatives | Expand the platform business for PHR services and data use by disease area, Promote data portability through diverse data linkages, including the linkage of test results through the MeDaCa service, Strengthen personalized services for users, including the PHR data business and treatment support through disease simulation, Strengthen the development of the medical institution network by providing services to local governments, including deemed health checkups and prevention of disease progression, Accelerate adoption of Mykarte ONC in collaboration with academic societies and other organizations, Launch a medical education platform business for patients, Strengthen data solutions through ePRO and registry studies for clinical research, Expand the business footprint through clinical research projects for pharmaceutical companies, Advance platform enhancements to drive a step change in the data business, Promote the use of PHR in targeted disease areas, Expand the business by providing PHR platforms organized by disease area, Increase revenue by developing a platform in the oncology area, Develop the data and research business, Launch and promote the medical education platform business for patients, Expand medical institution use in targeted disease areas and regions, Expand the business of preventing disease progression and encouraging medical consultations for insurers, Launch and promote a merchandise business combined with the use of PHR data, Expand the data and research business, Strengthen data solutions through ePRO and other services for clinical research, Expand the medical education platform business for patients, Launch treatment support through disease simulation, Expand the merchandise business combined with the use of PHR data |
| Size of the Target Market | Market B2B / Dimensions Approximately ¥250–¥360 billion / Breakdown Disease solutions business: ¥167.7 billion; Mykarte business: ¥78.5–¥193.5 billion / Source Fuji Keizai, “Future Prospects for the Seamless Integration and Cloudification of Healthcare IT and the Healthcare Big Data Business, No. 2” (2020); Yano Research Institute, “The Current State and Outlook of the Insurtech Market in Life Insurance Companies 2022”; Dentsu, “Advertising Expenditures in Japan”; Fuji Chimera Research Institute, “Comprehensive Survey of Wearable and Healthcare Businesses 2023”, Market B2M（B2B2M） / Dimensions Approximately ¥80–¥180 billion / Breakdown Mykarte business: ¥48.6–¥145.7 billion; real-world data business: ¥32.0 billion / Source Fuji Keizai, “Future Prospects for the Seamless Integration and Cloudification of Healthcare IT and the Healthcare Big Data Business, No. 1” (2020); Cabinet Office Secretariat of Science, Technology and Innovation Policy, “Strategic Innovation Creation Program (SIP): Strategy and Research and Development Plan for Building and Socially Implementing an Integrated Healthcare System”, Market B2B2C / Dimensions Approximately ¥660 billion (¥661.0 billion) / Breakdown Mykarte business and services for insurers / Source Ministry of Economy, Trade and Industry, “Promoting Health and Productivity Management” (March 2024), Market Target market (internal medicine institutions) / Dimensions 64,000 institutions / Breakdown Cardiology: 13,000; diabetology: 4,000; other internal medicine: 47,000 / Source Not disclosed, Market Target patients / Dimensions Hypertension: 24.5 million; diabetes: 8 million / Breakdown Not disclosed / Source Not disclosed |
| Risks identified | Handling of personal information: Patient privacy may be compromised by unforeseen events, such as the leakage of personal information, Competition: Competitive advantages may decline due to the entry of companies with high name recognition and broad customer bases, among other factors, Various regulations: The company may be required to respond to revisions, abolition or introduction of relevant laws and regulations or industry association rules, Seasonality of revenue: Revenue and profit tend to be concentrated in the fourth quarter, when the fiscal-year results of foreign-affiliated pharmaceutical companies are concentrated |
| Publication date | 2026/08/28 |
Items this document does not state (15)
Sales TargetOperating profit targetOperating profit margin targetNet income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planPlan assumptionsResults under the previous planReason for revision or withdrawalDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Solutions for corporate customers using the PHR platform in the disease solutions business have become a growth driver, and orders for the second half remain solid as the business enters the investment recovery phase. At the same time, costs are increasing due to upfront investments, including organizational expansion, aimed at future growth.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.